Incidence of the mucopolysaccharidoses in Northern Ir

Human Genetics

101, 355-358

DOI: 10.1007/s004390050641

Citation Report

#	Article	IF	Citations
1	The frequency of lysosomal storage diseases in The Netherlands. Human Genetics, 1999, 105, 151-156.	3.8	615
2	Clinical and laboratorial study of 19 cases of mucopolysaccharidoses. Revista Do Hospital Das Clinicas, 2000, 55, 213-218.	0.5	21
4	Lysosomal storage disorders: Diagnostic dilemmas and prospects for therapy. Genetics in Medicine, 2002, 4, 412-419.	2.4	32
5	Left ventricular aneurysm, aortic valve disease and coronary narrowing in a patient with Hunter's syndrome. Cardiovascular Pathology, 2002, 11, 94-96.	1.6	19
6	Direct estimates of human per nucleotide mutation rates at 20 loci causing mendelian diseases. Human Mutation, 2003, 21, 12-27.	2.5	308
7	Incidence of the mucopolysaccharidoses in Western Australia. American Journal of Medical Genetics Part A, 2003, 123A, 310-313.	2.4	185
8	Sleep Disorders in Sanfilippo Syndrome: A Polygraphic Study. Clinical EEG (electroencephalography), 2003, 34, 18-22.	0.9	26
9	Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Journal of Pediatrics, 2004, 144, 574-580.	1.8	267
10	Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Human Mutation, 2005, 26, 500-512.	2.5	140
11	Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). , 2005, 134A, 144-150.		130
12	Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the Î±-N-acetylglucosaminidase gene from the Okinawa islands in Japan. Journal of Human Genetics, 2005, 50, 357-359.	2.3	15
13	Cumulative incidence rates of the mucopolysaccharidoses in Germany. Journal of Inherited Metabolic Disease, 2005, 28, 1011-1017.	3.6	330
14	Mucopolysaccharidosis I: Î±-L-Iduronidase mutations in three Tunisian families. Journal of Inherited Metabolic Disease, 2005, 28, 1019-1026.	3.6	21
15	Neurological Manifestations in Lysosomal Storage Disorders - From Pathology to First Therapeutic Possibilities. Neuropediatrics, 2005, 36, 285-289.	0.6	31
16	Mucopolisacaridosis. EMC Pediatria, 2006, 41, 1-12.	0.0	0
17	Neurophysiologic assessment of mucopolysaccharidosis III. Clinical Neurophysiology, 2006, 117, 2059-2063.	1.5	10
18	Mucopolysaccharidosis type IV: N-Acetylgalactosamine-6-sulfatase mutations in Tunisian patients. Molecular Genetics and Metabolism, 2006, 87, 213-218.	1.1	23
20	Second-trimester diagnosis of mucopolysaccharidosis type IV a presenting as hydrops fetalis. Prenatal Diagnosis, 2006, 26, 750-752.	2.3	5

#	Article	IF	Citations
21	Prenatal diagnosis of congenital chylothorax associated withde novopartial trisomy 12q (12q21.2â†'qter). Prenatal Diagnosis, 2006, 26, 752-755.	2.3	5
22	Hurler's syndrome: dental findings in a case treated with bone marrow transplantation in infancy. International Journal of Paediatric Dentistry, 2006, 16, 207-212.	1.8	21
23	Recurrent Fetal Hydrops due to Mucopolysaccharidoses Type VII. Fetal Diagnosis and Therapy, 2006, 21, 250-254.	1.4	24
24	The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Molecular Genetics and Metabolism, 2007, 91, 37-47.	1.1	172
26	Management Guidelines for Mucopolysaccharidosis VI. Pediatrics, 2007, 120, 405-418.	2.1	214
27	Treatment of Lysosomal Storage Disorders. Drugs, 2007, 67, 2697-2716.	10.9	133
28	Mucopolysaccharidosis II (Hunter Syndrome). , 2007, , 407-414.		0
29	Common N-acetylgalactosamine-6-sulfate sulfatase (GALNS) exon mutations in Brazilian patients with mucopolysaccharidosis IVA (MPS IVA). Genetics and Molecular Biology, 2007, 30, 524-528.	1.3	1
30	A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 63-70.	1.5	112
31	International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease. Journal of Inherited Metabolic Disease, 2007, 30, 165-174.	3.6	278
32	Sanfilippo syndrome: A miniâ€review. Journal of Inherited Metabolic Disease, 2008, 31, 240-252.	3.6	303
33	Growth charts for patients affected with Morquio A disease. American Journal of Medical Genetics, Part A, 2008, 146A, 1286-1295.	1.2	122
34	Mucopolysaccharidoses in Brazil: What happens from birth to biochemical diagnosis?. American Journal of Medical Genetics, Part A, 2008, 146A, 1741-1747.	1.2	63
35	The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet Journal of Rare Diseases, 2008, 3, 24.	2.7	129
36	Heparin cofactor IIâ€"thrombin complex: A biomarker of MPS disease. Molecular Genetics and Metabolism, 2008, 94, 456-461.	1.1	54
37	The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 485-498.	2.0	161
38	Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opinion on Pharmacotherapy, 2008, 9, 311-317.	1.8	23
39	Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome). Pediatrics, 2008, 121, e377-e386.	2.1	260

#	Article	IF	Citations
40	Initial report from the Hunter Outcome Survey. Genetics in Medicine, 2008, 10, 508-516.	2.4	160
41	Mobility in Hurler Syndrome. Journal of Pediatric Orthopaedics, 2008, 28, 163-168.	1.2	59
42	AvaliaÃ§Ã£o da motricidade orofacial em pacientes com mucopolissacaridose: um estudo transversal. Jornal De Pediatria, 2009, 85, 254-260.	2.0	2
43	Mutational Analysis of the Î±-L-Iduronidase Gene in Three Egyptian Families: Identification of Three Novel Mutations and Five Novel Polymorphisms. Genetic Testing and Molecular Biomarkers, 2009, 13, 761-764.	0.7	3
44	The management of thoracic inlet syndrome associated with Hurler's syndrome: a novel surgical techniqueâ˜†. European Journal of Cardio-thoracic Surgery, 2009, 36, 1081-1083.	1.4	2
45	Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish republic. Archives of Disease in Childhood, 2009, 94, 52-54.	1.9	35
46	Incidence of the mucopolysaccharidoses in Taiwan, 1984â€“2004. American Journal of Medical Genetics, Part A, 2009, 149A, 960-964.	1.2	145
47	Clinical and biochemical studies in mucopolysaccharidosis type II carriers. Journal of Inherited Metabolic Disease, 2009, 32, 732-738.	3.6	12
48	Mucopolysaccharidoses type I and IVA: Clinical features and consanguinity in Tunisia. Pathologie Et Biologie, 2009, 57, 392-397.	2.2	13
49	Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Current Medical Research and Opinion, 2009, 25, 1285-1293.	1.9	48
50	Cervical Stenosis and Spastic Quadriparesis in Morquio Disease (MPS IV). Journal of Bone and Joint Surgery - Series A, 2009, 91, 438-442.	3.0	34
51	Anaesthetic considerations of adults with Morquio's syndrome - a case report. BMC Anesthesiology, 2010, 10, 2.	1.8	18
52	Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genetics and Molecular Biology, 2010, 33, 589-604.	1.3	150
53	Orthopedic management of mucopolysaccharide disease. Journal of Pediatric Rehabilitation Medicine, 2010, 3, 47-56.	0.5	45
55	Mucopolysaccharidosis VI. Orphanet Journal of Rare Diseases, 2010, 5, 5.	2.7	246
56	Morquio disease: The role of cartilage canals in the pathogenesis of chondrogenic dwarfism. Medical Hypotheses, 2010, 75, 642-644.	1.5	10
57	Prenatal diagnosis of the Hurler syndrome by microsatellite markers analysis. Immuno-Analyse Et Biologie Specialisee, 2010, 25, 38-42.	0.0	0
58	Identification and characterization of a novel homozygous deletion in the Î±-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB). Molecular Genetics and Metabolism, 2010, 100, 51-56.	1.1	20

#	Article	IF	Citations
59	Molecular characterization of MPS IIIA, MPS IIIB and MPS IIIC in Tunisian patients. Clinica Chimica Acta, 2011, 412, 2326-2331.	1.1	20
60	GM1 gangliosidosis and Morquio B disease: An update on genetic alterations and clinical findings. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 782-790.	3.8	115
62	Evaluation of Miglustat Treatment in Patients with Type III Mucopolysaccharidosis: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Pediatrics, 2011, 159, 838-844.e1.	1.8	28
63	Hurler disease (mucopolysaccharidosis type IH): clinical features and consanguinity in Tunisian population. Diagnostic Pathology, 2011, 6, 113.	2.0	12
64	Molecular analysis of mucopolysaccharidosis type I in Tunisia: identification of novel mutation and eight Novel polymorphisms. Diagnostic Pathology, 2011, 6, 39.	2.0	20
65	Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II. Diagnostic Pathology, 2011, 6, 42.	2.0	9
66	Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients. Diagnostic Pathology, 2011, 6, 47.	2.0	14
67	Genomic instability in blood cells from murine model of mucopolysaccharidosis type I. Journal of Molecular Histology, 2011, 42, 575-578.	2.2	5
68	Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet Journal of Rare Diseases, 2011, 6, 72.	2.7	183
69	Are MPS II heterozygotes actually asymptomatic? A study based on clinical and biochemical data, Xâ€inactivation analysis and imaging evaluations. American Journal of Medical Genetics, Part A, 2011, 155, 50-57.	1.2	12
70	A importÃ¢ncia da avaliaÃ§Ã£o otorrinolaringolÃ³gica de pacientes com mucopolissacaridose. Arquivos Internacionais De Otorrinolaringologia, 2011, 15, 290-294.	0.2	6
72	Histopathologic Changes of the Ear in Canine Models of Mucopolysaccharidosis Types I and VII. Veterinary Pathology, 2011, 48, 616-626.	1.7	5
73	Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review. Current Pharmaceutical Biotechnology, 2011, 12, 931-945.	1.6	178
74	Overview of the mucopolysaccharidoses. Rheumatology, 2011, 50, v4-v12.	1.9	384
75	A Description of Skeletal Manifestation in Adult Case of Morquio Syndrome: Radiographic and MRI Appearance. Case Reports in Medicine, 2012, 2012, 1-6.	0.7	7
76	Spinal cord infarction remote from maximal compression in a patient with Morquio syndrome. Journal of Neurosurgery: Pediatrics, 2012, 9, 608-612.	1.3	52
77	Subjective and Objective Assessment of Hand Function in Mucopolysaccharidosis IVa Patients. JIMD Reports, 2012, 9, 59-65.	1.5	21
79	Inner Ear Changes in Mucopolysaccharidosis Type I/Hurler Syndrome. Otology and Neurotology, 2012, 33, 1323-1327.	1.3	12

#	Article	IF	Citations
80	The Live-Birth Prevalence of Mucopolysaccharidoses in Estonia. Genetic Testing and Molecular Biomarkers, 2012, 16, 846-849.	0.7	18
81	Morquio A syndrome due to Maternal Uniparental Isodisomy of the telomeric end of chromosome 16. Molecular Genetics and Metabolism, 2012, 105, 438-442.	1.1	17
82	EstimaciÃ³n de las frecuencias de las mucopolisacaridosis y anÃ¡lisis de agrupamiento espacial en los departamentos de Cundinamarca y BoyacÃ¡. Biomedica, 2012, 32, .	0.7	21
83	Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Research and Reports in Endocrine Disorders, 2012, 2012, 65.	0.4	51
84	The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet Journal of Rare Diseases, 2013, 8, 101.	2.7	47
85	Transplantation of human umbilical mesenchymal stem cells cures the corneal defects of mucopolysaccharidosis VII mice. Stem Cells, 2013, 31, 2116-2126.	3.2	95
87	Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Molecular Genetics and Metabolism, 2013, 110, 54-64.	1.1	140
88	Newborn screening and diagnosis of mucopolysaccharidoses. Molecular Genetics and Metabolism, 2013, 110, 42-53.	1.1	131
89	A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet Journal of Rare Diseases, 2013, 8, 147.	2.7	69
90	Mucopolysaccharidosis IVA: Correlation between genotype, phenotype and keratan sulfate levels. Molecular Genetics and Metabolism, 2013, 110, 129-138.	1.1	54
91	Clinical overview and treatment options for nonâ€skeletal manifestations of mucopolysaccharidosis type IVA. Journal of Inherited Metabolic Disease, 2013, 36, 309-322.	3.6	79
92	Spinal involvement in mucopolysaccharidosis IVA (Morquioâ€Brailsford or Morquio A syndrome): presentation, diagnosis and management. Journal of Inherited Metabolic Disease, 2013, 36, 339-355.	3.6	100
93	Foot and Ankle Abnormalities in the Hurler Syndrome. Journal of Pediatric Orthopaedics, 2013, 33, 558-562.	1.2	13
94	Dental findings and oral health status in patients with mucopolysaccharidosis: a case series. Acta Odontologica Scandinavica, 2013, 71, 157-167.	1.6	18
95	Current and emerging management options for patients with Morquio A syndrome. Therapeutics and Clinical Risk Management, 2013, 9, 45.	2.0	20
96	In silico analysis of mutations occurring in the protein N-acetylgalactosamine-6-sulfatase (GALNS) and causing mucopolysaccharidosis IVA. Genetics and Molecular Research, 2014, 13, 10025-10034.	0.2	8
97	Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network. Genetics and Molecular Biology, 2014, 37, 23-29.	1.3	19
98	Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A) Tj ETQq1 1 0.784314 rgBT /Overlock	4.6	25

#	Article	IF	Citations
99	Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome. JIMD Reports, 2014, 19, 101-109.	1.5	14
100	Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome. Clinical Pharmacokinetics, 2014, 53, 1137-1147.	3.5	32
101	A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet Journal of Rare Diseases, 2014, 9, 173.	2.7	72
102	â€œGenotype-firstâ€•approaches on a curious case of idiopathic progressive cognitive decline. BMC Medical Genomics, 2014, 7, 66.	1.5	4
103	Morquio <scp>A</scp> Syndromeâ€Associated Mutations: A Review of Alterations in the GALNS Gene and a New Locusâ€Specific Database. Human Mutation, 2014, 35, 1271-1279.	2.5	59
104	Cytogenetic biomonitoring in mucopolyssacharosis I, II and IV patients treated with enzyme replacement therapy. Toxicology Mechanisms and Methods, 2014, 24, 603-607.	2.7	6
105	Sanfilippo syndrome, glucoseâ€6â€phosphate dehydrogenase deficiency and sickle cell/Î²⁺ thalassemia in a child: The burden of consanguinity. American Journal of Medical Genetics, Part A, 2014, 164, 267-269.	1.2	7
106	Mucopolysaccharidosis type IVA: Evidence of primary and secondary central nervous system involvement. American Journal of Medical Genetics, Part A, 2014, 164, 1162-1169.	1.2	19
107	Eight years experience from a skeletal dysplasia referral center in a tertiary hospital in Southern India: A model for the diagnosis and treatment of rare diseases in a developing country. American Journal of Medical Genetics, Part A, 2014, 164, 2317-2323.	1.2	18
108	Current and potential therapeutic strategies for mucopolysaccharidoses. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 215-224.	1.5	82
109	Cervicothoracic Myelopathy in Children With Morquio Syndrome A. Journal of Pediatric Orthopaedics, 2014, 34, 223-228.	1.2	17
110	Mortality in Patients with Morquio Syndrome A. JIMD Reports, 2014, 15, 59-66.	1.5	78
111	Morquio disease with CNS involvement: a rare association. Journal of Nepal Paediatric Society, 2014, 34, 157-159.	0.1	0
112	Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet Journal of Rare Diseases, 2014, 9, 21.	2.7	25
113	Brazilian reference values for MPS II screening in dried blood spots â€" A fluorimetric assay. Clinical Biochemistry, 2014, 47, 1297-1299.	1.9	4
114	Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses. Molecular Genetics and Metabolism, 2014, 113, 92-99.	1.1	30
116	Orthopedic management of the extremities in patients with Morquio A syndrome. Journal of Children's Orthopaedics, 2014, 8, 295-304.	1.1	45
117	Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placeboâ€controlled study. Journal of Inherited Metabolic Disease, 2014, 37, 979-990.	3.6	176

#	Article	IF	Citations
118	Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Molecular Genetics and Metabolism, 2014, 112, 160-170.	1.1	52
119	JIMD Reports, Volume 19. JIMD Reports, 2015, , .	1.5	0
120	Cervical Instability in Young Adults. Operative Techniques in Orthopaedics, 2015, 25, 202-208.	0.1	2
121	Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II. Molecular Genetics and Metabolism Reports, 2015, 2, 20-24.	1.1	12
122	Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial. Molecular Genetics and Metabolism, 2015, 114, 178-185.	1.1	65
123	Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clinical Therapeutics, 2015, 37, 1012-1021.e6.	2.5	43
124	Prevalence rates of mucopolysaccharidoses in Poland. Journal of Applied Genetics, 2015, 56, 205-210.	1.9	37
125	Mutations in ARSB in MPS VI patients in India. Molecular Genetics and Metabolism Reports, 2015, 4, 53-61.	1.1	13
126	Non-invasive pulmonary function test on Morquio patients. Molecular Genetics and Metabolism, 2015, 115, 186-192.	1.1	11
127	Optimizing the Molecular Diagnosis of GALNS: Novel Methods to Define and Characterize Morquio-A Syndrome-Associated Mutations. Human Mutation, 2015, 36, 357-368.	2.5	26
128	Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: Early treatment rescues bone lesions?. Molecular Genetics and Metabolism, 2015, 114, 195-202.	1.1	28
129	International guidelines for the management and treatment of Morquio A syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 11-25.	1.2	104
130	Carbohydrate-Processing Enzymes of the Lysosome. Advances in Carbohydrate Chemistry and Biochemistry, 2016, 73, 225-302.	0.9	18
131	Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. The Cochrane Library, 2016, 3, CD009806.	2.8	16
132	Lower Extremity Deformity Management in MPS IVA, Morquio-Brailsford Syndrome: Preliminary Report of Hemiepiphysiodesis Correction of Genu Valgum. Journal of Pediatric Orthopaedics, 2016, 36, 376-381.	1.2	23
133	Mucopolisacaridosis. EMC Pediatria, 2016, 51, 1-14.	0.0	1
134	Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995â€“2012. Orphanet Journal of Rare Diseases, 2016, 11, 85.	2.7	26
135	Current therapies for Morquio A syndrome and their clinical outcomes. Expert Opinion on Orphan Drugs, 2016, 4, 941-951.	0.8	28

#	Article	IF	Citations
136	Workshop Proceedings. International Journal of Toxicology, 2016, 35, 393-409.	1.2	1
137	Clinical course of sly syndrome (mucopolysaccharidosis type VII). Journal of Medical Genetics, 2016, 53, 403-418.	3.2	133
138	Bone mineral density in mucopolysaccharidosis IVB. Molecular Genetics and Metabolism Reports, 2016, 8, 80-84.	1.1	11
139	Management of Life-Threatening Tracheal Stenosis and Tracheomalacia in Patients with Mucopolysaccharidoses. JIMD Reports, 2016, 33, 33-39.	1.5	16
140	Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. Journal of Human Genetics, 2016, 61, 345-349.	2.3	28
141	The utility of two dimensional electrophoresis in diagnosis of mucopolysaccharidosis disorders. Clinica Chimica Acta, 2016, 457, 36-40.	1.1	3
142	Characterization of a Case of Pigmentary Retinopathy in Sanfilippo Syndrome Type IIIA Associated with Compound Heterozygous Mutations in the SGSH Gene. Ophthalmic Genetics, 2016, 37, 217-227.	1.2	7
143	Elevation of glycosaminoglycans in the amniotic fluid of a fetus with mucopolysaccharidosis VII. Prenatal Diagnosis, 2017, 37, 435-439.	2.3	20
144	Hallazgos audiolÃ³gicos en niÃ±os con mucopolisacaridosis tipos i - iv. Acta OtorrinolaringolÃ³gica EspaÃ±ola, 2017, 68, 262-268.	0.4	3
145	Mucopolysaccharidoses seen in adults in rheumatology. Joint Bone Spine, 2017, 84, 663-670.	1.6	17
147	Epidemiology of mucopolysaccharidoses. Molecular Genetics and Metabolism, 2017, 121, 227-240.	1.1	290
148	Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study. Clinical Therapeutics, 2017, 39, 118-129.e3.	2.5	24
149	Audiological Findings in Children With Mucopolysaccharidoses Type Iâ€“IV. Acta Otorrinolaringologica (English Edition), 2017, 68, 262-268.	0.2	2
150	Bio-Plex immunoassay measuring the quantity of lysosomal N -acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study. BMJ Open, 2017, 7, e014410.	1.9	7
151	Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels. Molecular Genetics and Metabolism Reports, 2017, 11, 46-53.	1.1	17
152	Oral manifestations in children with mucopolysaccharidosis. Medical Express, 2017, 4, .	0.2	3
153	A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Molecular Therapy, 2018, 26, 1366-1374.	8.2	141
154	Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet Journal of Rare Diseases, 2018, 13, 53.	2.7	53

#	Article	IF	Citations
155	Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Molecular Genetics and Metabolism, 2018, 124, 216-227.	1.1	9
157	A 16-year-old Girl with Morquio Syndrome: A Case Report. BIRDEM Medical Journal, 2018, 8, 266-269.	0.1	0
158	Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet Journal of Rare Diseases, 2018, 13, 84.	2.7	50
159	Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique. BMC Research Notes, 2018, 11, 28.	1.4	7
160	Health service security of patients with 8 certain rare diseases: evidence from Chinaâ€™s national system for health service utilization of patients with healthcare insurance. Orphanet Journal of Rare Diseases, 2019, 14, 204.	2.7	14
161	Clinical, biochemical and genetic profiles of patients with mucopolysaccharidosis type IVA (Morquio A) Tj ETQq1 1 0.784314 rgBT /Overl Diseases, 2019, 14, 143.	2.7	9
162	Oral manifestation and root canal therapy of the patient with mucopolysaccharidosis. Restorative Dentistry & Endodontics, 2019, 44, e14.	1.5	3
163	Effect of enzyme replacement therapy on the growth of patients with Morquio A. Journal of Human Genetics, 2019, 64, 625-635.	2.3	32
164	Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2019, 25, e226-e246.	2.0	110
165	Otolaryngologists and the Early Diagnosis of Mucopolysaccharidoses: A Cross-Sectional Study. Diagnostics, 2019, 9, 187.	2.6	2
166	Safety Study of Sodium Pentosan Polysulfate for Adult Patients with Mucopolysaccharidosis Type II. Diagnostics, 2019, 9, 226.	2.6	8
167	Estimated birth prevalence of mucopolysaccharidoses in Brazil. American Journal of Medical Genetics, Part A, 2020, 182, 469-483.	1.2	20
168	Ocular Tolerability and Immune Response to Corneal Intrastromal AAV-IDUA Gene Therapy in New Zealand White Rabbits. Molecular Therapy - Methods and Clinical Development, 2020, 18, 24-32.	4.1	9
169	Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies. BioMed Research International, 2020, 2020, 1-18.	1.9	22
170	Epidemiology of Mucopolysaccharidoses Update. Diagnostics, 2021, 11, 273.	2.6	50
171	Pectus carinatum as the key to early diagnosis of Morquio A syndrome: a case report. Journal of Medical Case Reports, 2021, 15, 150.	0.8	0
172	Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet Journal of Rare Diseases, 2021, 16, 241.	2.7	33
173	Demographic, clinical, and ancestry characterization of a large cluster of mucopolysaccharidosis IV A in the Brazilian Northeast region. American Journal of Medical Genetics, Part A, 2021, 185, 2929-2940.	1.2	5

#	Article	IF	Citations
174	Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 1225-1235.	0.9	12
175	Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. The Cochrane Library, 2021, 2021, CD009806.	2.8	2
176	Impairment of Body Growth in Mucopolysaccharidoses. , 2012, , 2091-2117.		15
177	Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany. PLoS ONE, 2013, 8, e66804.	2.5	10
178	Evaluation of orofacial motricity in patients with mucopolysaccharidosis: a cross-sectional study. Jornal De Pediatria, 2009, 85, 254-260.	2.0	14
179	A second reported malignancy in a patient with Morquio syndrome. Autopsy and Case Reports, 2017, 7, 9-14.	0.6	3
180	Mucopolysaccharidoses and Oligosaccharidoses. , 2000, , 414-421.		2
181	Mucopolysaccharidosis I. , 2007, , 389-405.		0
182	Skeletal Dysplasias. , 2008, , 1677-1794.		1
183	Morquios Syndrome: A Rare Case Report. Journal of Indian Academy of Oral Medicine and Radiology, 2013, 25, 63-65.	0.3	1
184	Morquio Syndrome. , 2014, , 1-3.		0
185	Dwarf with dual spinal kyphotic deformity at the cervical and dorsal spine unassociated with odontoid hypoplasia: Surgical management. Journal of Pediatric Neurosciences, 2016, 11, 237.	0.3	0
186	Molecular-genetic characterization of Ukrainian patients with mucopolysaccharidosis IIIA: identification of three new mutations in the heparan-N-sulfatase gene. Biopolymers and Cell, 2016, 32, 359-366.	0.4	0
187	Identification and characterization of six new mutations in GLB1 gene in Ukrainian patients with GM1 gangliosidosis and Morquio B disease. Biopolymers and Cell, 2016, 32, 450-460.	0.4	2
188	Morquio Syndrome. , 2018, , 1167-1169.		0
189	Apoptosis status and proliferative activity in mucopolysaccharidosis type I mice tongue mucosa cells. Dental Research Journal, 2012, 9, S69-74.	0.6	0
190	Assessment of the function and morphology of the thyroid gland in paediatric patients treated with enzyme replacement therapy due to selected storage diseases â€“ preliminary results of our own research and a review of the literature. Pediatric Endocrinology, Diabetes and Metabolism, 2022, , .	0.7	0
191	Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA. Molecular Genetics and Metabolism Reports, 2022, 31, 100869.	1.1	0

#	Article	IF	Citations
192	Lysosomal Storage Disorders. , 0, , 778-791.		0
193	The GALNS p.P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome. BMC Genomics, 2022, 23, .	2.8	1
194	Twenty years of Colombian experience with enzymatic screening in patients with features of mucopolysaccharidosis. JIMD Reports, 2022, 63, 475-483.	1.5	1
195	Quantification of Idua Enzymatic Activity Combined with Observation of Phenotypic Change in Zebrafish Embryos Provide a Preliminary Assessment of Mutated idua Correlated with Mucopolysaccharidosis Type I. Journal of Personalized Medicine, 2022, 12, 1199.	2.5	2
196	Hurler Syndrome: Orofacial Clinical Findings. Cureus, 2023, , .	0.5	0
197	Clinical Characteristics of a Patient with Mucopolysaccharidosis Type IVA (Morquio Syndrome). Voprosy Sovremennoi Pediatrii - Current Pediatrics, 0, , .	0.4	0
198	Hallazgos ecocardiogrÃ¡ficos de pacientes pediÃ¡tricos con mucopolisacaridosis tipo IV-A con mutaciÃ³n c.901G>T en el gen GALNS en un centro de salud de cuarto nivel de Colombia en el periodo de 2012-2019. Medicas UIS, 2022, 35, .	0.0	0
199	A Neonate with Mucopolysaccharidosis Type VII with Intractable Ascites. AJP Reports, 2023, 13, e25-e28.	0.7	1
200	Anaesthetic challenges faced in a child with Morquio syndrome- An orphan disease. Indian Journal of Clinical Anaesthesia, 2023, 10, 98-101.	0.1	0
201	Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme. Pharmaceuticals, 2023, 16, 931.	3.8	0